Immune surveillance of EBV-infected B cells and the development of non-Hodgkin lymphomas in immunocompromised patients. - Wikidata - wikimedia - TriplyDB

Immune surveillance of EBV-infected B cells and the development of non-Hodgkin lymphomas in immunocompromised patients.

Immune surveillance of EBV-infected B cells and the development of non-Hodgkin lymphomas in immunocompromised patients.

http://www.wikidata.org/entity/Q37152749

about

Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective Immune Activation: Contribution to AIDS-Associated Non-Hodgkin Lymphoma Adverse events in IBD: to stop or continue immune suppressant and biologic treatment Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease.Burkitt lymphoma: pathogenesis and immune evasion.Epstein-Barr virus replication linked to B cell proliferation in inflamed areas of colonic mucosa of patients with inflammatory bowel disease Current status of immunotherapy for the treatment of lung cancer.Effect of Medications on Risk of Cancer in Patients With Inflammatory Bowel Diseases: A Population-Based Cohort Study from Olmsted County, Minnesota Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disorders Rapid reconstitution of CD4 T cells and NK cells protects against CMV-reactivation after allogeneic stem cell transplantation.Oral eosinophilic ulcer, an Epstein-Barr virus-associated CD30+ lymphoproliferation?Lymphoma in inflammatory bowel disease and treatment decisions.Sequential Hodgkin's and non-Hodgkin's lymphoma in non-immunocompromised patients.Xenophagy in Helicobacter pylori- and Epstein-Barr virus-induced gastric cancer.Monitoring for Extra-Intestinal Cancers in IBD.The Effect of Antiretroviral Combination Treatment on Epstein-Barr Virus (EBV) Genome Load in HIV-Infected Patients.Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection.Malaria, Epstein-Barr virus infection and the pathogenesis of Burkitt's lymphoma.HIV Co-receptor usage in HIV-related non-hodgkin's lymphoma.Controlled Epstein-Barr virus reactivation after allogeneic transplantation is associated with improved survival.Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma.Association between oral lichen planus and Epstein-Barr virus in Iranian patients.

P2860

Q26745456-FB30C1DE-0C19-443A-9660-7A6FB4C9CB3D Q28079644-A3D6F5F4-C1B9-4725-A466-DE3DEDB41EF7 Q33887336-8DEF4346-C771-4ABB-A3D1-39485B695F41 Q34073191-32E0416B-DE6B-4BB5-9759-DB108827E145 Q34078707-C8A912A3-AA51-4CD9-AAAD-CC5081054132 Q34189497-10D56E89-5271-4B31-971F-1ED5C98C378E Q34644510-3B922054-1E73-4A36-A311-FBF68745EA77 Q35667739-EC265E85-D60E-408D-8536-BA4D96E0E869 Q35690314-FD6C4C83-A088-426C-8662-1C228141DA18 Q35738744-C35EED7C-0E27-453C-934B-20253611C624 Q37148363-096482CA-F31C-41D0-9838-3AF3C34AC105 Q37861459-021592C9-C32A-4E90-AD02-98F06527EB4A Q38024070-41DC9160-711F-4B9D-A8F1-04596BDF6198 Q38096296-F7D7C478-440F-4034-8A9F-C2DD7F40A617 Q38196348-D4BCE04F-AFCA-468A-A1E9-5E9A7E251C85 Q38585910-D0E89B65-B8B3-406B-A21C-C16644767A9F Q38615024-D9F1177F-DD1E-4C08-8710-936C8EE02745 Q38853095-4885E6BE-F1AD-4DBF-97DC-4727CD281B66 Q40123116-14FA2692-0F07-48CF-977E-349D11CF1539 Q42138493-B0602E03-1934-4028-804B-C30282E7027D Q42244554-47445BBB-126B-4851-B749-50F81C7DDF5C Q47266595-280B2767-1F5A-4A6C-AF62-361254006D58 Q54228581-FC78AB4E-DABC-462A-9E87-DE1C4EB83DBF

P2860

Immune surveillance of EBV-infected B cells and the development of non-Hodgkin lymphomas in immunocompromised patients.

http://www.wikidata.org/entity/Q37152749

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Immune surveillance of EBV-inf ...... in immunocompromised patients.

@en

Immune surveillance of EBV-inf ...... in immunocompromised patients.

@nl

type

label

Immune surveillance of EBV-inf ...... in immunocompromised patients.

@en

Immune surveillance of EBV-inf ...... in immunocompromised patients.

@nl

prefLabel

Immune surveillance of EBV-inf ...... in immunocompromised patients.

@en

Immune surveillance of EBV-inf ...... in immunocompromised patients.

@nl

P1433

Q37152749-90D82138-3D02-4196-BEDF-C8E7FBBDC1BF

P1476

Q37152749-89EFCC23-9630-459D-9667-ED32777FD9D3

P2093

Q37152749-0ECD2260-A194-4FDF-B931-329600C1CB21

Q37152749-8F051DB4-C26D-4277-B67B-2069A22C0E13

Q37152749-9638678D-EBA3-4258-BFD1-E6406A8B07D4

P2860

Q37152749-052AFA53-1C18-41A2-AD4F-32A9E2668963

Q37152749-067D1BA0-6D61-4BD3-92A4-90114B339E22

Q37152749-09CD0DCE-4C9E-4C27-AA62-D1C05C20CFCF

Q37152749-0D4B9AC7-813E-41E8-8335-27448E499064

Q37152749-106D8A2B-B13F-4D6F-B0D5-967BE3364A63

Q37152749-10757EA4-E161-4F18-88B2-1E3029FA6C8F

Q37152749-12AA26C3-790F-42AF-BFA2-2C961AD76927

Q37152749-12AC7E79-66A7-4C12-8A08-755A44B0C409

Q37152749-1419AECE-B96F-4A59-8C1F-4C2DF87343B9

Q37152749-1424D23C-EA45-46B5-9731-B56D9D7CC21C

P304

Q37152749-D30EBF82-0323-4D19-98F4-462FD26BF066

P31

Q37152749-7BEE6774-5A23-49E7-B613-04C48FEF92ED

P356

Q37152749-54468DFB-8A3F-461C-87C7-4A090BF72260

P433

Q37152749-692500F1-DE2E-4895-9747-4CD4E50B9583

P478

Q37152749-4DD7D123-391B-48A5-92F2-815209147601

P577

Q37152749-75957D1B-FE05-485A-B705-212D9E517C51

P698

Q37152749-453121A2-411B-4B48-B510-7039CEDE7E4B

P921

Q37152749-2C74C2E2-1660-4E04-8DDD-C4478A65E201

P356

10428190801911662

P1433

Leukemia & Lymphoma

P1476

Immune surveillance of EBV-inf ...... in immunocompromised patients.

@en

P2093

Debbie van Baarle

http://www.w3.org/2001/XMLSchema#string

Erwan Piriou

http://www.w3.org/2001/XMLSchema#string

Floor Pietersma

http://www.w3.org/2001/XMLSchema#string

P2860

Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.

Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT.

Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.

Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy

Relative dominance of epitope-specific cytotoxic T-lymphocyte responses in human immunodeficiency virus type 1-infected persons with shared HLA alleles

B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS.

HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals.

High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation.

P304

1028-1041

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428190801911662

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P577

2008-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18452077

http://www.w3.org/2001/XMLSchema#string

P921